AIM
ADMA icon

Ausbil Investment Management’s ADMA Biologics ADMA Stock Holding History

Ausbil Investment Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-97,591
Closed -$1.78M – 64
2025
Q4 		$1.78M Sell
97,591
-4,323
-4% -$72.9K 1.01% 31
2025
Q3 		$1.53M Buy
101,914
+21,421
+27% +$367K 0.82% 33
2025
Q2 		$1.47M Sell
80,493
-26,376
-25% -$538K 0.86% 34
2025
Q1 		$2.12M Buy
106,869
+98,743
+1,215% +$1.71M 1.29% 29
2024
Q4 		$150K Buy
+8,126
New +$153K 0.09% 62

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Ausbil Investment Management's ADMA Position: Q1 2026 in Review

Ausbil Investment Management sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 97,591 shares — an estimated $1.78M sold.

Ausbil Investment Management first reported a position in ADMA in Q4 2024 and held it in 5 quarters. The position peaked at $2.12M in Q1 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Ausbil Investment Management reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Ausbil Investment Management sold 97,591 ADMA Biologics shares in Q1 2026, an estimated $1.78M.
  • Ausbil Investment Management first reported a position in ADMA Biologics in Q4 2024 and held it in 5 quarters.
  • Ausbil Investment Management's ADMA Biologics position peaked at $2.12M in Q1 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Ausbil Investment Management's 13F filing for Q1 2026, filed 8 Apr 2026.